Keqi Pharmaceutical is a developer of innovative tumor immunotherapy drugs, focusing on the R&D and clinical application of innovative tumor immunotherapy drugs, and wholly-owned holding Shanghai Keqi Pharmaceutical Technology Co., Ltd. referred to as “Keqi Pharmaceutical”). Based on clinical needs and corporate positioning focusing on tumor immunotherapy, the company has deployed R&D platforms such as bifunctional antibodies, ADCs, CAR-T for solid tumors, and CAR-T for hematological tumors, and has developed nearly 8 FIC/BIC products. Recently, Keyi Pharmaceutical completed the first round of financing of nearly 500 million yuan, which was invested by Kequan Fund established by Zhejiang Anji Development Zone. The funds will be mainly used for clinical trials of core products, IND filing of core pipelines and construction of GMP plants.
This article is reproduced from: https://www.itjuzi.com/investevent/13644018
This site is for inclusion only, and the copyright belongs to the original author.